Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial. Solid Biosciences Inc. (NASDAQ:SLDB) today reported …
Solid Biosciences financial results and business updateRead More
Changing Places, Changing Lives
This Friday, 11th May, one of our Trustees, Shelley, will be taking part in a campaign to raise awareness of the need for more Changing Places …
Wave Life Sciences financial results and update
Wave Life Sciences have announced financial results for the first quarter ended March 31, 2018, and provided a business update. “The …
Action Duchenne co-funding new research bringing new hope for Duchenne muscular dystrophy
Barts Charity and Action Duchenne have combined forces to support research into new stem cell therapies for Duchenne Muscular Dystrophy. With a …
Action Duchenne co-funding new research bringing new hope for Duchenne muscular dystrophyRead More
Alderwood Recruitment hold bake sale for Action Duchenne
Amazing effort by Alderwood at last week's charity bake sale for Action Duchenne- we raised £155! Thank you so much to every one who baked as …
Alderwood Recruitment hold bake sale for Action DuchenneRead More
Delay in access to Exondys 51
Last week, at the European Medicine’s Agency (EMA) the Committee for Medicinal Products for Human Use (CHMP) held a hearing …
Please opt in
GDPRIn order to continue our exceptional work we need your consent in line with the new GDPR rules. We need to receive your …
Capricor Announces Initiation of HOPE-2 Clinical Trial Of CAP-1002 for Duchenne Muscular Dystrophy
Capricor Therapeutics has announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Centre. The trial will test the safety …
Catabasis present new data showing significantly slowed Duchenne disease progression
Yesterday Catabasis reported new positive magnetic resonance efficacy results showing slowed disease progression in boys with Duchenne in the MoveDMD …
Catabasis present new data showing significantly slowed Duchenne disease progressionRead More
Daiichi Sankyo announce results of Phase 1/2 clinical trial
Daiichi Sankyo have announced the top-line results of the Phase 1/2 clinical trial in Japan of DS-5141 which Daiichi Sankyo is jointly developing with …
Daiichi Sankyo announce results of Phase 1/2 clinical trialRead More
Thank You – An announcement on the Early Access to Medicines Scheme for Raxone
We are delighted to announce that the MHRA have decided to maintain a positive opinion on the Early Access to Medicines Scheme for Raxone to treat …
Thank You – An announcement on the Early Access to Medicines Scheme for RaxoneRead More
Summit Presents New 24-Week Analyses from PhaseOut DMD trial
Data show correlation between decrease in muscle damage and reduction in muscle inflammation in patients treated with ezutromid Summit Therapeutics …
Summit Presents New 24-Week Analyses from PhaseOut DMD trialRead More
